No Data
No Data
CSE Bulletin: Suspension - BioVaxys Technology Corp. (BIOV)
Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2024) - Effective immediately, BioVaxys Technology Corp. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defi
Press Release: BIOVAXYS APPOINTS CHRISTOPHER CHERRY AS CHIEF FINANCIAL OFFICER
BIOVAXYS APPOINTS CHRISTOPHER CHERRY AS CHIEF FINANCIAL OFFICER Canada NewsWire VANCOUVER, BC, April 30, 2024 VANCOUVER, BC, April 30, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB)
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
VANCOUVER, BC, and MADISON, Wis. , April 10, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac-for-Wildlife, Inc. ("SpayVac") jointly annou
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE
VANCOUVER, B.C., April 3, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has received a Notice of Allowance from the
BioVaxys Technology Plans Private Placement; Down 5.9%
BioVaxys Technology Corp. (BIOV.CN) said Monday that it plans to raise gross proceeds of up to C$1 million via a non-brokered private placement. The offering will comprise nearly 15.4 million units at
BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT
VANCOUVER, BC, March 22, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") announces that it intends to complete a non-brokered privat